Background: Lung transplantation is the only treatment modality that provides a survival advantage in pulmonary fibrosis, but many patients deemed suitable will die awaiting lung transplantation. While donor organ shortage undoubtedly contributes to this, late referral to the transplant centre may also play a role. This study investigates factors influencing the chance of patients with pulmonary fibrosis reaching lung transplantation.
Methods: A single-centre retrospective review of patient demographic data, assessment investigations and subsequent clinical outcomes was performed for patients with pulmonary fibrosis assessed for lung transplantation over a 5-year period.
Results: Between March 1999 and March 2004, 129 patients with pulmonary fibrosis underwent formal transplant assessment. Sixty-nine were accepted and listed for lung transplantation. Of these, 17 were transplanted, 37 died while waiting, 4 were removed from the list and 11 were still waiting at the conclusion of the study. The median waiting time on the list for those transplanted was 103 days (range 6–904) compared with 125 days (range 2–547) for those who died while on the list (p = 0.65). There was no significant difference in age, spirometry, total lung capacity, gas transfer measures or 6 min walk distance between those who died waiting and those transplanted. However, time from onset of symptoms to transplant assessment was significantly shorter in those who died on the waiting list (median 29 months (range 2–120)) than in those transplanted (median 46 months (range 6–204), p = 0.037).
Conclusion: Patients with pulmonary fibrosis who died awaiting transplantation had similar disease severity at assessment as those who achieved transplantation. However, the interval between symptom onset and transplant referral was significantly shorter in those who died while on the waiting list, suggesting they had more rapidly progressive disease. The rate of disease progression appears to be a more sensitive indicator for transplantation referral than any single physiological measure of disease severity and should act as an important trigger for early transplant referral.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Pulmonary fibrosis is a progressive debilitating restrictive lung disease which, in most cases, is fatal within 3–5 years of diagnosis.1–4 It is currently recommended that patients diagnosed with pulmonary fibrosis initially receive treatment with corticosteroids and immunosuppressive therapy.5 There is, however, no evidence that this improves survival or reduces the rate of disease progression. Lung transplantation is the only treatment modality that provides an actuarial survival advantage in this population.6 The progressive nature of this disease and the short interval between diagnosis and death make this therapeutic option available only to a limited number of younger patients. The transplant process begins with referral to a specialist transplant centre. Those without an absolute contraindication are thereafter admitted for detailed inpatient assessment. Patients accepted onto the active waiting list will wait on average 12–18 months for a suitable donor organ in the UK.7 Consequently, many patients never achieve transplantation and die while on the waiting list. While donor organ availability undoubtedly contributes to this, patients with pulmonary fibrosis have the highest waiting list mortality of all patients awaiting lung transplantation,8 and the unpredictable natural history of this disease—together with late referral for transplant assessment—may play an important role in this statistic.
Timely assessment is important in all patients under consideration for lung transplantation, none more so than those with pulmonary fibrosis in whom the window of opportunity for transplant may be as little as 22 months.9 Referral criteria suggest that all patients under the age of 65 years who are symptomatic and have failed to respond to steroid and immunosuppressive therapy should be considered for transplantation.10 More specifically, a vital capacity of <60% predicted or transfer factor of <50% predicted should trigger referral. Waiting list mortality has remained high despite these guidelines, and it has been suggested that they do not adequately allow for the unpredictable and progressive nature of this disease. New guidelines published recently have attempted to address this issue, and suggest that all patients with usual interstitial pneumonia (UIP), irrespective of vital capacity, or fibrotic non-specific interstitial pneumonia (NSIP) should be assessed.11 However, such criteria are broad and require firm histological diagnosis that may not be easily accessible to all referring clinicians. In view of this, we reviewed the experience at our centre over a 5-year period, comparing those who died while on the waiting list with those who reached transplantation. Our principal aim was to identify objective differences that may help refine referral criteria and subsequently impact on survival in this population.
A retrospective review of all patients with pulmonary fibrosis who underwent formal inpatient assessment for lung transplantation at our centre between March 1999 and March 2004 was performed. Patient case notes were used to extract baseline demographic data, histopathological diagnosis, ABO blood group, body mass index and the results of pulmonary function tests, arterial blood gas measurement and unencouraged 6 min walk test distance. Patients were categorised as having idiopathic pulmonary fibrosis (IPF)/UIP or non-IPF because of the tendency of IPF/UIP to run a more rapidly progressive course. The diagnosis of IPF was based on the characteristic findings on biopsy and high-resolution CT scanning in those who died and from the explant pathology in those transplanted. In some cases where it was unclear which subtype of idiopathic interstitial pneumonia (IIP) was present, patients were assigned “unclassified IIP”.
The clinical course of those listed for transplantation was followed thereafter until September 2004. In addition, we examined the length of time between each stage in the transplant process: (1) symptom onset to assessment; (2) assessment to listing; and (3) listing to transplantation.
Our aims were to identify objective differences in demographic measures, physiological measures and clinical course between those transplanted and those who died on the waiting list in order to refine referral criteria.
Analysis of data
All demographic and clinical data (excluding static lung volumes and transfer factor) are expressed as mean (SD). All remaining data are expressed as median (range). Statistical analysis was performed using the Student unpaired t test for parametric data, Mann-Whitney U test for non-parametric data, and χ2 test and Fisher exact test. (Microsoft Excel and Arcus Quickstat). A p value of <0.05 was considered significant.
One hundred and twenty-nine patients (92 men) of mean (SD) age 53 (7) years with pulmonary fibrosis, referred from 54 centres, underwent formal inpatient assessment between March 1999 and March 2004. Median time from symptom onset to first transplant assessment was 36 months (range 2–240). Of these 129 patients, 69 (53%) were listed for transplantation. Of the remaining 60 patients who were not listed, only 3 were deemed too unwell at the time of assessment. Thirty of the 60 not listed had significant co-morbidities which acted as a contraindication to transplantation, the commonest of which were ischaemic heart disease and obesity. Nineteen of the 60 were deemed too well for transplantation at the time of assessment. Importantly, we found no significant difference in spirometry or static lung volumes, exercise capacity or degree of hypoxia between those listed and those not. However, those who were not listed had a significantly higher transfer factor, indicating that this group had less advanced disease.
Of the 69 patients listed for transplantation, 37 (54%) died while on the waiting list while 17 (25%) were transplanted. Eleven patients remained alive on the list at the end of the study and 4 were removed from the list (fig 1).
Fifteen (88%) of those transplanted and 27 (73%) of those who died while on the waiting list had a diagnosis of IPF/UIP based on pathology with or without radiology (table 1). In five patients who died we were unable accurately to assign a subtype of IIP and have classified them as “unspecified IIP”. There was no significant difference in the proportions with IPF and non-IPF between those transplanted and those who died while on the waiting list (p = 0.3, Fisher exact test).
Time course of assessment, listing and transplantation
The median time from symptom onset to initial lung transplantation assessment was significantly shorter in patients who died while on the waiting list than in those who underwent transplantation (29 months (range 2–120) vs 46 months (range 6–204); p = 0.037, Mann-Whitney U test). There was no significant difference between patients who died on the waiting list and those who were transplanted in time from assessment to listing (median 60 days (range 4–998) vs 48 days (range 7–305); p = 0.32, Mann-Whitney U test). The two groups spent similar lengths of time on the transplant waiting list (median 103 days (range 6–904) for those transplanted vs 125 days (range 2–547) for those who died on the waiting list; p = 0.65, Mann-Whitney U test).
Baseline demographic data
There was no significant difference in age, 6 min walk distance, desaturation on walk test and body mass index between those who died while on the waiting list and those who underwent transplantation (table 2). An arterial blood gas analysis was performed on all patients at transplantation assessment. For clinical reasons it was necessary to perform this test in some while receiving supplementary oxygen. Therefore, in addition to comparing the degree of hypoxia between those transplanted and those who died while on the waiting list, we allocated patients receiving oxygen to have an arterial oxygen tension (Pao2) <8 kPa (indicating respiratory failure) and compared those with Pao2 <8 kPa with those with Pao2 >8 kPa. There was no significant difference in Pao2 and Paco2 (table 2) and in the proportion with Pao2 <8 kPa and >8 kPa (p = 0.5, χ2 test) between those transplanted and those who died while on the waiting list. Lung function was also compared as an objective marker of disease severity. There was no difference in mean percentage predicted forced expiratory volume in 1 s or vital capacity and no difference in median total transfer factor, transfer factor corrected for alveolar volume or total lung capacity between those transplanted and those who died while on the waiting list, among those who were able to complete reliable lung function testing (table 2).
In some cases patients were unable to complete full testing as illustrated in table 2. We therefore investigated by χ2 analysis and Fisher exact tests whether there were significant differences in the proportion of patients transplanted and those who died while waiting in terms of who could and could not complete tests (table 3). No significant differences were found, except for the measurement of vital capacity where those transplanted were less likely to be able to perform this manoeuvre.
Presence of pulmonary hypertension
Echocardiograms were performed at assessment on all patients to investigate the incidence and degree of concomitant pulmonary hypertension. Adequate views in order to make an assessment of pulmonary artery pressure were available in 119 cases (92%). A pulmonary artery systolic pressure (PASP) of >50 mm Hg estimated via tricuspid regurgitant velocity was taken as evidence of pulmonary hypertension. Sixteen patients (30%) had documented pulmonary hypertension. We found no significant difference in the presence or absence of pulmonary hypertension between those transplanted and those who died on the waiting list (p = 0.2, χ2 test). In addition, among those with documented pulmonary hypertension, there was no difference in severity (mean (SD) estimated PASP 59 (10) mm Hg (7 patients transplanted) vs. 65 (11) mm Hg (9 patients died on list) (p = 0.3, unpaired t test).
Thirty-seven patients who were blood group O were listed, of whom only 5 were transplanted. In contrast, 9 of the 25 patients with blood group A received a transplant and 3 of 5 with blood group B were transplanted (p = 0.042, χ2 test). No patients with blood group AB received a transplant in this cohort.
Patients with pulmonary fibrosis have the highest waiting list mortality of all those awaiting lung transplantation, and new more sensitive triggers to determine the optimal timing of transplant referral are urgently needed. In this study we found that patients who died while on the transplant waiting list had similar disease severity based on spirometry, static lung volumes, gas transfer factor, degree of hypoxia, incidence of pulmonary hypertension and 6 min walk test to those who achieved transplantation. However, those who died waiting were referred earlier, with a significantly shorter interval between symptom onset and referral for transplantation assessment. These findings suggest that those who died on the waiting list reached the level requiring transplantation more rapidly. There was no significant difference between groups in time spent on the waiting list. From these observations, we believe that those who died on the waiting list had more rapidly progressive disease, with a shorter interval from symptoms to assessment, and subsequent continued rapid decline while on the waiting list. In further support of this theory, we found no significant difference in time between assessment and listing, and listing and transplantation (ie, days spent on the transplant list) between the two groups. Thus, delays in listing and longer wait times on the transplant list do not account for the excess mortality in those on the waiting list.
These findings are in agreement with a recently published smaller study that showed no difference in conventional physiological predictors but found a similar difference in time from diagnosis to referral.12 Timmer et al13 also noted a trend towards shorter time from diagnosis to referral for patients who died on the waiting list, but these differences (43.2 months among those alive on the waiting list vs 20.9 months among those who died) did not reach significance. These studies support our hypothesis that the rate of disease progression has an important role in determining the chance of achieving transplantation. Collard et al14 showed that changes in dyspnoea score, total lung capacity, vital capacity and oxygen saturation over 6 months were predictive of survival and advocated that such change may provide more accurate prognostic information than baseline physiological measurements alone. Hanson and colleagues15 reported that changes in vital capacity and single breath transfer factor after 1 year of treatment strongly predictive of survival time in patients with IPF. A 10% reduction in vital capacity or 20% reduction in single breath transfer factor after 1 year predicted poorer survival than those patients with unchanged or improved tests. Data were, however, only compared at 1 year so the actual rate of physiological decline and the impact on survival remains unknown.
The pathological classification in pulmonary fibrosis is a most informative guide with regard to prognosis and an accurate diagnosis is always sought.16 Diagnosis has been refined by the new classification system of IIP.16 Patients were assigned a diagnosis of IPF based on clinical history and characteristic findings on high-resolution CT scanning and biopsy. However, as is frequently encountered in clinical practice, despite best efforts, some patients do not receive a firm diagnosis as evidenced by those with “unspecified IIP”. Thus, even with greater correlation between histology and clinicoradiological findings, a firm diagnosis is not always reached even after biopsy.12 17 The presence of another causative factor (such as connective tissue disease or exposure to asbestos) can make a correct diagnosis more elusive. In this study, two patients whose pretransplant diagnosis was connective tissue disease-associated fibrosis and two who were thought to have NSIP and desquamative interstitial pneumonia, respectively, were confirmed as having UIP when the pathology of their explanted lung was reviewed.
UIP is the commonest form of IIP and has the worst prognosis18; however, other forms are also referred for transplantation as witnessed in this study. Evidence suggests that the survival advantage conveyed by NSIP does not emerge until 18–24 months after diagnosis.19 Clinicians should not be falsely reassured by a diagnosis of NSIP as these patients can be misdiagnosed or present with rapidly progressive phenotypes that mimic UIP. Importantly, most patients referred for transplantation come from centres without specific expertise or services in fibrotic lung disease. The heterogeneous nature of this cohort of patients and, indeed, the underlying disease process therefore make our findings pertinent. The rate of physiological and symptomatic decline in any form of pulmonary fibrosis appears to provide a simple accessible tool that may be of greater prognostic value than the underlying pathological diagnosis in patients considered for transplantation.
Pao2 is reported to predict survival in this population,13 but we found no difference in the degree of hypoxia or the presence of respiratory failure (as defined by Pao2 <8 kPa) in our cohort, thus supporting our theory that patients who died while on the waiting list had similar disease severity to those transplanted. Similarly, the 6 min walk test has been shown to predict poorer survival,20 with a distance of <207 m having a fourfold greater rate of mortality than those with a walk distance greater than this distance. In our study, while we found no significant difference between those transplanted and those who died while on the waiting list, those who died had a mean walk distance of 199 m which is in keeping with these findings. The performance of this test on supplemental oxygen may have allowed some to achieve higher than expected walk distances, thus masking this result.
The presence of pulmonary hypertension was shown to correlate with survival in patients with pulmonary fibrosis in a study by Nadrous and colleagues.21 They stratified patients into three groups depending on PASP (<35 mm Hg, 36–50 mm Hg, >50 mm Hg) and then followed them for 4.8, 4.1 and 0.8 years, respectively. Those with PASP >50 mm Hg had a significantly worse survival when analysed by the Kaplan-Meier method. In our study we found no difference in the presence or degree of pulmonary hypertension between those who died while on the waiting list and those transplanted. The measurements of PASP obtained by echocardiography may have been too insensitive to detect a difference between these two groups.
Importantly, ABO blood group did influence the chance of achieving transplantation with patients of blood groups A and B being more likely to receive a transplant. While this finding should not be directly used in referral criteria, it may have a role in the decision-making process at transplant assessment in group O patients who are moving beyond the transplant window of opportunity, directing treatment towards a palliative approach.
The use of explant lung pathology to establish classification of IIP in those transplanted is by definition limited to only one group. This may introduce bias. We took this strategy in order that those transplanted were not assumed to have forms of pulmonary fibrosis with a better prognosis than UIP/IPF.
Incomplete data are inevitable in this retrospective “real life” observational study of clinical practice. To investigate any confounding this might cause, we examined whether significant differences existed in the proportions of those able to complete tests and those not (ie, whether disease severity in either group was masked by incomplete data). We found no such difference, except for vital capacity, where those transplanted were less able to complete the manoeuvre. Thus, at assessment, we believe that all patients accepted onto the transplant waiting list had similar disease severity.
This retrospective review encounters the biases and limitations that feature in all such studies. The data were, however, collected prospectively during detailed inpatient assessment, with all tests performed over a 4-day period. We acknowledge that the data on time to referral depends on accurate referral information. Another limitation is the lack of serial spirometric and gas transfer measures, providing information on the actual rate of decline in lung function. These data are not currently available as patients on the transplant waiting list do not generally have serial measures of lung function performed routinely as such repeated tests were previously thought to be of limited value. It could also be considered that these observations simply reflect local practice in the UK, although recent changes in the organ allocation system in the USA make these observations internationally relevant.
In conclusion, we have shown that patients who died on the lung transplant waiting list were referred earlier than those who were transplanted. These two groups did not differ significantly in lung function indices, 6 min walk test or degree of hypoxia, suggesting that when assessed they had similar disease severity. We believe that those who died on the waiting list had more rapidly progressive disease as evidenced by the shorter time from symptom onset to assessment. This study suggests that the rate of progression of disease may provide an indication of when to refer patients with pulmonary fibrosis for lung transplantation assessment. Further work is now required to investigate the rate of change in these patients and to determine the magnitude and velocity required to trigger transplant referral.
Funding: LSM is a Clinical Research Associate funded by AstraZeneca. RLA is a Clinical Research Associate funded by an ERS fellowship. AJF is funded by a GlaxoSmithKline Senior Clinical Fellowship.
Competing interests: None
- idiopathic interstitial pneumonia
- idiopathic pulmonary fibrosis
- non-specific interstitial pneumonia
- Paco2, arterial oxygen and carbon dioxide tensions
- pulmonary artery systolic pressure
- usual interstitial pneumonia